Uzbekistan Power of Attorney and Legalization Chain for Medical Device Registration

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

For a power of attorney issued by a foreign manufacturer to acquire full legal effect between the country of issuance and Uzbekistan, a document drawn up in Chinese must complete three steps in sequence: notarization in the country of issuance → notarized certification of the accuracy of the Uzbek translation (required by registration decree No. 3888, applicable from October 8, 2026) → apostille or consular legalization. The order of the three steps cannot be reversed, and each step involves a different competent authority. Placing the translation certification after the legalization step is the most common cause of rework in practice, because documents that have already been legalized must be processed again once the translation is certified separately. The practical consequence is calendar risk: the chain involves at least three authorities and two international mailings, none of which can run in parallel. Since the power of attorney underpins every action the authorized representative performs before the Center, from the initial submission through renewal, variations and the receipt of decisions, any defect in the chain does not merely delay one filing; it can freeze the entire regulatory workstream for the product line. Planning the chain as a scheduled critical path, with the power of attorney template confirmed before the technical dossier is finalized, is the reliable way to keep the sequence intact and avoid repeat legalization.

2. Legal basis

RegulationNumberDateProvision
Rules for the Preparation of Medical Device Registration Dossiers (registration decree)No. 3888Registered July 2026, effective October 8, 2026A power of attorney submitted by a representative must be notarized, apostilled or consularly legalized; where the power of attorney is drawn up in a language other than Uzbek, Karakalpak, Russian or English, the accuracy of its Uzbek translation must be notarized
Cabinet Resolution approving the Regulation on the Procedure for State Registration of Medicines and Medical Devices and the Issuance of Registration CertificatesNo. 738Adopted November 24, 2025, effective February 26, 2026Annex 2a: submissions made through a representative must be accompanied by documents evidencing the authority of the representative
Cabinet Resolution approving the Regulation on the Procedure for State Registration of Medicines, Medical Use Products and Medical Equipment and the Issuance of Registration Certificates (superseded by Resolution No. 738)No. 213March 23, 2018 (amended December 7, 2023)Article 12: documents may be submitted directly, by mail, or in electronic form, with electronic form confirmed by an electronic digital signature
Cabinet Resolution approving the Regulation on the Procedure for State Registration of Medicines and Medical Devices and the Issuance of Registration CertificatesNo. 738Adopted November 24, 2025, effective February 26, 2026The power of attorney should identify the correct legal entity, signing authority, the scope of devices or products, the permitted actions and the period of validity

3. Expert insights

Insight 1: registration decree No. 3888 defines the language rule down to four specific languages. Powers of attorney drawn up in Uzbek, Karakalpak, Russian or English require no additional translation certification; all other languages, including Chinese, do. This rule creates a practical option: reissuing the power of attorney in an English version can remove the translation certification step entirely. Before taking that route, two points must be confirmed: the English version must be legally equivalent to the original document, and the signing entity and the wording of the granted authorities must be identical to those in the original. Where the manufacturer is a Chinese entity and the original corporate authorization is drafted in Chinese, an English reissue should be checked against the parent authorization to ensure no divergence in scope.

Insight 2: apostille and consular legalization are alternatives, not cumulative requirements. The wording of registration decree No. 3888 is notarization, apostille or consular legalization. The document flow route between the two countries should be determined according to the international conventions and bilateral arrangements in force at the time, and one of the two options is sufficient. Processing both not only adds cost but may cause the document to be rejected because of a conflict in its legal form. Verifying the current route with the receiving authority before starting the chain is cheaper than redoing the legalization after a rejection.

Insight 3: the content of the power of attorney should cover the full lifecycle to avoid repeat processing. The power of attorney should identify the correct legal entity, the signing authority, the scope of devices or products, the permitted actions and the period of validity. If it only authorizes the submission of a registration application, then the entire legalization chain must be processed again for renewal, variation and adverse event reporting. This is the most expensive kind of omission, because each reissuance restarts notarization, translation certification and legalization from the beginning.

Insight 4: the legalization chain is a non-compressible segment of the project schedule. The three steps involve at least three authorities and two international mailings, and none of them can run in parallel. GRZAN manages the chain as a critical path item and recommends confirming the power of attorney template before the technical dossier is finalized, so that document revisions do not trigger a new round of notarization and legalization. Building this buffer into the project plan protects the submission date.

4. Practical recommendations

  1. Schedule the legalization chain in a fixed order: notarization in the country of issuance → translation certification → apostille or consular legalization.
  2. Scope the power of attorney to cover submission, renewal, variations, receipt of decisions and post-market support, completing it once to avoid repeat processing.
  3. Evaluate reissuing the power of attorney in an English version to remove the translation certification step, after confirming legal equivalence.
  4. Confirm the power of attorney template before the technical dossier is finalized, so that document revisions do not trigger re-legalization.
  5. Retain the processing receipts and completion dates for every step to support later review and expiry management.

5. Verification checklist

  • □ The power of attorney has completed notarization in the country of issuance
  • □ The power of attorney drawn up in Chinese has completed notarized certification of the accuracy of its Uzbek translation
  • □ Apostille or consular legalization has been completed, choosing one option and not processing both
  • □ The authority of the power of attorney covers submission, renewal, variations, receipt of decisions and post-market support
  • □ The power of attorney template was confirmed before the technical dossier was finalized
  • □ Processing receipts and completion dates for every step have been retained

GRZAN supports manufacturers, importers and authorized representatives with medical device registration, power of attorney legalization planning and market access in Uzbekistan. For assistance with your product portfolio, contact info@grzanglobal.com.

Regulatory information verified as of October 29, 2026.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail